Evogene Announces Filing of Annual Report on Form 20-F

Rhea-AI Summary

Evogene (EVGN) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023. The report can be accessed on the Company's investor relations website and the SEC's website. Security holders can request a hard copy for free.

REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.

The Annual Report on Form 20-F can be accessed on the Company's investor relations website https://evogene.com/investor-relations/ and on the SEC's website at http://www.sec.gov. The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI.  Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

1.  Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;

2.  Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;

3.  AgPlenus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;

4.  Canonic Ltd. (www.canonicbio.com) – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and

5.  Casterra Ag Ltd. (www.casterra.co)– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com. 

Contact

Rachel Pomerantz Gerber

Head of Investor Relations at Evogene

rachel.pomerantz@evogene.com

Tel: +972-8-9311901

Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/evogene-announces-filing-of-annual-report-on-form-20-f-302102466.html

SOURCE Evogene

FAQ

Where can I find Evogene 's Annual Report on Form 20-F for the fiscal year ended December 31, 2023?

You can access the Annual Report on the Company's investor relations website and the SEC's website.

How can Evogene 's security holders request a hard copy of the Annual Report?

Security holders can request a hard copy for free by visiting the Contact Us page on the Company's website.